Therefore, in this prospective study, our aim was to evaluate the utility of pre-treatment cfDNA concentration to predict the prognosis of NSCLC patients that are to receive anti-PD-(L)1 antibodies. This evidence concerns the gene CD274 and non-small cell lung carcinoma.